Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
XXII 22nd Century Group Inc
ALEC Alector Inc
BABA Alibaba Group Holding Ltd
JEQ abrdn Japan Equity Fund, Inc.
BAC Bank of America Corp
RVLWF Revitalist Lifestyle and Wellness Ltd
$NQUS45101010LMEURN Nasdaq US Brewers Large Mid Cap Net
$R25IG Russell 2500 Growth Index
TTC Toro Co
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Closing Price
$245.17
Day's Change
-1.36 (-0.55%)
Bid
--
Ask
--
B/A Size
--
Day's High
249.96
Day's Low
242.21
Volume
(Average)
Volume:
3,072,989

10-day average volume:
2,918,776
3,072,989

AMGN's position in the Biotechnology industry

Industry PeersAMGNGILDREGNVRTXALNY

Summary

Company ProfileAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human...
Go to GILD summary
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines...
Go to REGN summary
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several...
Go to VRTX summary
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and...
Go to ALNY summary
52-Week Change

VS. INDUSTRY
9.43%
29.22%
26.17%
23.50%
63.76%
Market Cap

VS. INDUSTRY
$130.9B
$106.0B
$85.3B
$77.3B
$28.7B
Beta

VS. INDUSTRY
0.6
0.4
0.2
0.5
0.5
Dividend Yield

VS. INDUSTRY
3.48%
3.55%
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
20.24x
23.22x
20.48x
23.76x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$26.3B
$27.3B
$12.2B
$8.7B
$960.9M
Profit Margin

VS. INDUSTRY
24.89%
16.74%
35.64%
37.62%
-123.02%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
1.96%
-13.86%
23.79%
--
--
Revenue Growth (TTM)

VS. INDUSTRY
1.32%
-0.09%
-24.26%
22.03%
28.24%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.